Merck's Vioxx penalty was $950 million. It arrived eight years after the drug was pulled.

By ··1 min read·2 sources

Merck pleaded guilty to a misdemeanor. It did not admit the civil allegations about cardiovascular safety.

Merck agreed in November 2011 to pay $950 million over its marketing of the painkiller Vioxx. It pleaded guilty to a misdemeanor for promoting the drug for rheumatoid arthritis before the FDA approved that use, and was sentenced in April 2012 to a $321.6 million fine.

A $628.4 million civil settlement covered broader allegations, including that Merck representatives made inaccurate or misleading statements about Vioxx's cardiovascular safety. Merck said the agreement was not an admission of liability.

The timeline is the indictment of the system. Vioxx was withdrawn in September 2004 after it was linked to heart attacks and strokes. The off-label promotion continued after an FDA warning letter in 2001. Sentencing came in 2012.

The criminal case was narrow and the safety claims were settled without admission. By the time the penalty landed, the drug had been off the market for eight years and the revenue long since booked.

Sources

  1. justice.gov · justice.gov/opa/pr/2011/November/11-civ-1524.html
  2. justice.gov · justice.gov/archives/opa/pr/us-pharmaceutical-company-merck-sharp-dohme-sentenced-connecti…

Cite this report

The Precedent. "Merck's Vioxx penalty was $950 million. It arrived eight years after the drug was pulled.." September 10, 2026. https://theprecedent.org/article/mercks-vioxx-penalty-was-950-million-it-arrived-eight-years-after-the-drug-was-p

Companies in this report